GSK is ramping up its oncology clinical trials to nearly 20 by 2027 as it prepares for patent expirations on its key HIV drug franchise. This strategic pivot aims to build new revenue sources, though the success of these efforts will depend on clinical outcomes and regulatory approvals.
GlaxoSmithKline (GSK) is aggressively shifting its focus toward oncology, aiming to double the number of its late-stage cancer clinical trials by 2027. The company currently manages around 15 clinical-stage assets and expects to increase this to between 19 and 20 by next year. This move is a direct effort to replace potential revenue losses from its existing HIV drug portfolio, which faces major patent expirations in the coming years.
The pharmaceutical industry often faces a 'patent cliff,' where the legal protection for a blockbuster drug ends, allowing cheaper generic versions to enter the market and drastically reduce sales. With its HIV franchise serving as a significant revenue driver, GSK is under pressure to develop new, high-value treatments to sustain its long-term financial health.
To achieve this, the company is adopting an accelerated development strategy. This approach involves moving certain drug candidates directly into late-stage trials, skipping traditional mid-stage hurdles to speed up the time it takes to get products to market. While this can shorten timelines, it also increases risks, as skipping traditional steps can sometimes make it harder to predict the eventual success of a drug. Cancer treatments account for nearly half of the seven drug programs currently on this fast-track path.
This initiative marks a major institutional shift for GSK. Over a decade ago, the company had exited the oncology space, later deciding to re-enter the market to tap into the high-growth potential of cancer therapies. Today, its efforts are centered on assets like Jemperli (dostarlimab), a targeted therapy. In the first half of 2026, the company's oncology segment reported revenue of £1.08 billion, highlighting the importance of this sector to its bottom line.
For investors, the primary concern lies in the high-risk nature of drug development. Oncology is a highly competitive and complex field, and there is no guarantee that these accelerated trials will lead to successful, approved treatments. Failure in late-stage trials can result in significant financial losses and wasted research efforts, given the massive amount of money companies spend on drug trials.
Moving forward, the success of this strategy will depend on clinical data, safety results, and the speed of regulatory approvals. Investors will likely track the company's progress on trial outcomes, how effectively the new drugs move through the pipeline, and whether the company can maintain its profit margins while spending heavily on this new R&D push.